Philips (AEX: PHIA / NYSE ADR: PHG) traded at approximately €17 per share in early 2026, roughly 65% below its January 2021 peak of €52. The stock has been in a prolonged decline since the June 2021 DreamStation sleep apnea recall as the company continues paying settlement costs and rebuilding investor trust in its health technology business.
Stock Price of Philips
Euronext Amsterdam share price (EUR) — ticker PHIA. Data from 1912 listing through early 2026. The 2021 crash reflects the DreamStation recall announcement. The 2000 peak reflects the full consumer electronics era.
Philips Stock Forecast
Analyst sentiment on PHIA is cautiously optimistic for 2026. Most 12-month price targets range from €18 to €28, conditional on recall costs finally peaking and the health technology division showing sustainable margin improvement. The bull case rests on a full DreamStation settlement and a return to profitability. The key risk is further regulatory action or remediation cost overruns. Philips's imaging systems and monitoring businesses remain structurally sound.
Philips Valuation
Timeline of Philips Funding
-
1891
Founder CapitalFrederik Philips provides personal capital of 75,000 Dutch guilders to fund the Eindhoven factory, where son Gerard Philips designs and manufactures the first carbon-filament light bulbs for European markets.
-
1912
Amsterdam Stock Exchange ListingPhilips lists on the Amsterdam Stock Exchange, raising public equity capital that funds rapid expansion into radio components, X-ray tubes, and early consumer electronics across Europe.
-
1987
NYSE ADR ListingPhilips begins trading on the New York Stock Exchange as an ADR (PHG), broadening access to US institutional capital at a time when it was competing directly with Japanese consumer electronics companies.
-
2016
Signify Partial IPOPhilips spins off its lighting business as Signify via an IPO on Euronext Amsterdam, unlocking capital and simplifying Philips into a pure health technology company with a cleaner investment thesis.
-
2024
DreamStation SettlementPhilips reaches a $1.1 billion settlement with US regulators and class action plaintiffs over the DreamStation sleep apnea recall, partially funded from cash reserves and a €1.5 billion debt refinancing completed in 2023.